fruquintinib + eribulin

Fruquintinib + eribulin is a combination therapy currently under clinical investigation for the treatment of advanced malignancies, specifically triple-negative breast cancer (TNBC). Fruquintinib is a potent and highly selective oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, designed to inhibit tumor angiogenesis while minimizing off-target toxicities. Eribulin is a non-taxane microtubule dynamics inhibitor that disrupts mitotic spindles, causing cell cycle arrest in the G2/M phase and subsequent apoptosis. The combination is being explored to enhance therapeutic efficacy in patients with refractory breast cancer, with studies led by institutions such as Jiangsu Cancer Hospital evaluating its safety and anti-tumor activity.

Other names

fruquintinib and eribulineribulin and fruquintinib